Brokerages Set Solventum Corporation (NYSE:SOLV) Target Price at $91.64

Solventum Corporation (NYSE:SOLV) has received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $91.6364.

SOLV has been the topic of a number of recent analyst reports. Stifel Nicolaus upped their target price on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. BTIG Research lifted their price target on shares of Solventum from $91.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings raised shares of Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. KeyCorp upped their price target on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Saturday, August 22nd.

Solventum Stock Down 1.6%

Shares of NYSE SOLV opened at $90.21 on Wednesday. Solventum has a 1 year low of $62.38 and a 1 year high of $94.16. The firm has a market cap of $15.36 billion, a price-to-earnings ratio of 11.03, a PEG ratio of 1.43 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. The stock’s 50-day simple moving average is $84.53 and its 200-day simple moving average is $76.25.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.15 billion. During the same quarter in the prior year, the business posted $1.69 earnings per share. Solventum’s revenue for the quarter was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities analysts anticipate that Solventum will post 7.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently modified their holdings of the stock. CrossGen Wealth LLC acquired a new position in Solventum in the fourth quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new stake in Solventum during the third quarter valued at approximately $25,000. Clearstead Trust LLC raised its stake in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares in the last quarter. CYBER HORNET ETFs LLC bought a new position in Solventum during the 2nd quarter worth approximately $28,000. Finally, Modus Advisors LLC bought a new position in Solventum during the 4th quarter worth approximately $30,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.